The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) found to be active and safe in relapsed/refractory classical Hodgkin lymphoma.
Lauren M. Green
Advertisement
Articles by Lauren M. Green
Advertisement
Latest Updated Articles
Relapsed Hodgkin Lymphoma Combination Shows PromisePublished: December 8th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Regular Melatonin Supplementation May Hide Hidden Heart Complications
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
COVID-19 During Pregnancy Raises Neurodevelopmental Risks in Children
4
Early Detection of Type 1 Diabetes: The Power of Screening and Preparation
5
